Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065506 | 1.00 | SCN2A (0.44) | SCN2ASCN10ANAMPTTDP1KDM4E | |
| SCHEMBL2064735 | 0.88 | CHRNB4 (0.48) | SCN2ASCN10ANAMPTKDM4EPKM | |
| SCHEMBL2064737 | 0.88 | CHRNB4 (0.48) | SCN2ASCN10ANAMPTKDM4EPKM | |
| SCHEMBL2065410 | 0.86 | SCN10A (0.44) | SCN2ASCN10ANAMPTTDP1KDM4E | |
| SCHEMBL2065411 | 0.86 | SCN10A (0.44) | SCN2ASCN10ANAMPTTDP1KDM4E | |
| SCHEMBL1134582 | 0.80 | SCN2A (0.50) | SCN2ASCN10ACHRNB4CHRNA3 | |
| SCHEMBL2065268 | 0.78 | USP30 (0.45) | GPR119MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2065041 | 0.78 | USP30 (0.45) | GPR119MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2065039 | 0.78 | USP30 (0.45) | GPR119MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2065904 | 0.78 | CHRNB4 (0.47) | LMNACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700639-A1 | Selective ligands for the neuronal nicotinic receptors and uses thereof | Abbvie Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8648084-B2 | Selective substituted pyrazine ligands for neuronal nicotinic receptors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8148408-B2 | Selective substituted pyridine ligands for neuronal nicotinic receptors | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | CHRNA4, CHRNB4, CHRNA2 | SCN2A 106/4885SCN10A 152/4885NAMPT 344/4885 |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | CHRNA4, CHRNB4, CHRNA2 | SCN2A 113/4885SCN10A 139/4885NAMPT 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.